AEON gets FDA Type 2b feedback on ABP-450 biosimilar pathway for BOTOXSep 30Quarterly updateAEON Biopharma, Inc.onabotulinumtoxina
AbbVie posts IMGN632 BPDCN results; opens NOA LIFT filler trial vs VOLIFTSep 4Weekly roundup, 4 itemsAbbVieIMGN632
AbbVie posts Crohn's OLE results; registers Phase 3 lung cancer and Phase 1 glabellar lines trialsAug 13Weekly roundup, 3 itemsABBV-1480AbbVie
AEON Biopharma reports Q2 2026 results, cites new financing and FDA meeting on ABP-450Aug 12FinancingAEON Biopharma, Inc.
AbbVie week: BOTOX oral pain results post; new CLL, myeloma, ABBV-859 trials filedJul 31Weekly roundup, 6 itemsABBV-859AbbVie
AEON Biopharma closes $13.75 million offering with attached milestone warrantsJul 15FinancingAEON Biopharma, Inc.
AbbVie posts TEMPLE Phase 3 results for atogepant vs topiramate; opens three early-stage trialsJul 2Weekly roundup, 5 itemsABBV-313AbbVie
Sign inSign in